POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER).
Potassium is the major intracellular cation, essential for maintenance of normal cell function, nerve impulse transmission, and muscle contraction. Replacement therapy restores potassium levels in hypokalemia.
| Metabolism | Potassium is not metabolized; it is absorbed from the gastrointestinal tract and primarily excreted by the kidneys. |
| Excretion | Primarily renal (90%), with fecal elimination accounting for approximately 10%. Excretion is via glomerular filtration, with tubular reabsorption and secretion adjusting potassium balance. |
| Half-life | Not applicable as potassium is an endogenous ion; however, the biological half-life for serum potassium redistribution and excretion is approximately 1-1.5 hours in individuals with normal renal function. In renal impairment, half-life may be prolonged and requires dose adjustment. |
| Protein binding | Not significantly protein-bound (<5%). |
| Volume of Distribution | Approximately 0.5 L/kg in healthy individuals, reflecting distribution primarily in intracellular and extracellular fluid. Neonates may have a higher Vd (up to 0.6 L/kg). |
| Bioavailability | Oral: approximately 90-100% for immediate-release formulations; sustained-release forms have slightly lower bioavailability but are still 80-100%. Intravenous: 100%. |
| Onset of Action | Intravenous: onset within minutes for ECG effects; oral: onset of action typically within 30 minutes to 1 hour for serum potassium elevation. |
| Duration of Action | Duration is dependent on ongoing potassium balance; for acute intravenous correction, effects may last 2-4 hours after infusion; oral sustained-release forms provide action over 6-8 hours. |
| Molecular Weight | 74.55 |
20 mEq intravenously over 1 hour, repeated as needed based on serum potassium levels. Maximum infusion rate 10 mEq/hour. Maximum daily dose 200 mEq.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-60 mL/min: reduce dose by 50% or monitor serum potassium closely. GFR <30 mL/min: avoid use or use with extreme caution (maximum 10 mEq/h, monitor ECG and K+). |
| Liver impairment | No specific adjustment required for Child-Pugh A or B. Child-Pugh C: monitor serum potassium closely as risk of hyperkalemia may be increased due to impaired potassium handling. |
| Pediatric use | 0.5-1 mEq/kg/dose intravenously, maximum 20 mEq/dose, infused at a rate not exceeding 0.5 mEq/kg/hour. Repeat based on serum potassium levels. |
| Geriatric use | Initiate at lower end of dosing range (e.g., 10 mEq intravenously over 1 hour). Monitor renal function and serum potassium frequently due to age-related decline in renal function. |
| 1st trimester | Potassium chloride is essential for cellular function; however, high doses can cause maternal hyperkalemia, which may affect fetal cardiac function. Use only if clearly needed and monitor serum potassium levels. |
| 2nd trimester | Same as T1. Use with caution, avoiding hyperkalemia. Potassium chloride is generally considered safe when used within therapeutic ranges. |
| 3rd trimester | Potassium chloride is commonly used in pregnancy for hypokalemia. High doses near term may cause maternal hyperkalemia with potential fetal effects. Use only when necessary. |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER).
| Placental transfer | Potassium crosses the placenta by active transport and diffusion. Maternal hyperkalemia can lead to elevated fetal potassium; the placenta maintains a gradient. Transfer is regulated but clinically relevant with high maternal levels. |
| Breastfeeding | Potassium chloride is a normal constituent of breast milk; levels reflect maternal serum levels. Supplementation does not significantly alter milk potassium. However, monitor infant for signs of hyperkalemia if maternal doses are high. Generally considered compatible with breastfeeding. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | No evidence of teratogenic risk; potassium chloride is an essential electrolyte. First trimester: no known embryotoxic effects. Second and third trimesters: no known fetal harm, but maternal hyperkalemia can cause fetal arrhythmias and neonatal depression. High doses may affect fetal acid-base balance. |
| Fetal Monitoring | Monitor serum potassium, renal function, and ECG. In pregnancy, monitor for signs of hyperkalemia (weakness, arrhythmias). Fetal monitoring indicated only with maternal severe electrolyte disturbances or arrhythmias. |
| Fertility Effects | No known adverse effects on human fertility. Potassium homeostasis is essential for reproductive function; no evidence of fertility impairment with therapeutic use. |
■ FDA Black Box Warning
None
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria or anuriaConcurrent use of potassium-sparing diureticsAdrenal insufficiency (e.g., Addison disease)Acute dehydrationExtensive tissue breakdown (e.g., severe burns, crush injuries)Concurrent use of ACE inhibitors or ARBs with elevated potassiumMetabolic acidosis (especially in chronic renal failure)
| Precautions | Administer with caution in patients with renal impairment, severe burns, or adrenal insufficiency., Too rapid administration may cause fatal hyperkalemia and cardiac arrest., Monitor serum potassium levels during therapy., Do not administer unless solution is clear and container undamaged. |
| Food/Dietary | Avoid high-potassium foods (bananas, oranges, potatoes, spinach, tomatoes, avocados) and salt substitutes containing potassium chloride. Do not use additional potassium supplements. Consistent dietary potassium intake is important; consult dietitian for individualized plan. |
| Clinical Pearls | Potassium chloride 20 mEq in a plastic container (typically premixed IV solution) is used for correction of hypokalemia. Infuse via a central line if concentration >10 mEq/hr; peripheral administration can cause phlebitis. Never administer undiluted as a bolus; maximum infusion rate is 10 mEq/hr (or 20 mEq/hr in critical care with continuous ECG monitoring). Monitor serum potassium and renal function; risk of hyperkalemia in renal impairment. Do not co-infuse with blood products. Plastic containers may leach DEHP; use within 24 hours after spiking. |
| Patient Advice | This medication is given through a vein to treat or prevent low potassium levels. · You may have an ECG monitor to check your heart rhythm during infusion. · Tell your nurse immediately if you feel pain, redness, or swelling at the IV site. · Do not eat high-potassium foods, salt substitutes, or potassium supplements without asking your doctor. · Report symptoms of high potassium: muscle weakness, irregular heartbeat, or tingling in hands/feet. |
Loading safety data…